879132-49-7

Basic information

• Product Name: 5-nitro-1'-((2-(triMethylsilyl)ethoxy)Methyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one
• Synonyms: 5-nitro-1'-((2-(triMethylsilyl)ethoxy)Methyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one
• CAS NO: 879132-49-7
• Molecular Formula: C₂₁H₂₅N₃O₄Si
• Molecular Weight: 411.5264
• Mol File: 879132-49-7.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-nitro-1'-((2-(triMethylsilyl)ethoxy)Methyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-nitro-1'-((2-(triMethylsilyl)ethoxy)Methyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one(879132-49-7)
• EPA Substance Registry System: 5-nitro-1'-((2-(triMethylsilyl)ethoxy)Methyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one(879132-49-7)

Safety Data

• Hazardous Substances Data: 879132-49-7(Hazardous Substances Data)

Upstream product

• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 22162-19-2 (4-nitro-1,2-phenylene)dimethanol 
• 610-27-5 4-nitrophthalic acid 
• 879132-47-5 3,3-dibromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-dihydro-2H-pyrrolo[2.3-b]pyridin-2-one 
• 271-63-6 7-Azaindole 
• 879132-46-4 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine 
• 6425-66-7 1,2-bis-bromomethyl-4-nitro-benzene 
• 879132-48-6 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 

Downstream Products

• 957130-49-3 (R)-5-amino-1,3-dihydrospiro[indene-2,3’-pyrrolo[2,3-b]pyridin]-2’(1’H)-one 
• 957121-35-6 tert-butyl (S)-(2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)carbamate 
• 957121-34-5 tert-butyl (R)-(2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)carbamate 
• 1033608-31-9 tert-butyl (+/-)-(2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)carbamate 
• 1059185-34-0 2-[5-(3,5-difluorophenyl)-3-ethyl-5-methyl-2,4-dioxoimidazolidin-1-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide 
• 1189570-37-3 (2R)-5-({2-[(8R)-8-(3-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfanyl)-1'-{[2-(trimethylsiryl)ethoxy]methyl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-41-2 (2S)-6-{(1E)-3-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]prop-1-en-1-yl}-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridine]-5-carbonitrile 
• 1189569-38-7 (2R)-5-({2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfinyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-08-1 (2R)-5-{3-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]prop-1-yn-1-yl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-37-6 (2R)-5-({2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfanyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-34-3 (2R)-5-{(1E)-3-[2-(3,5-difluorophenyl)-5-(fluoromethyl)-2,4,5-trimethyl-6-oxopiperazin-1-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-40-1 (2R)-5-{(1E)-3-[(7R,9aR)-7-(3,5-difluorophenyl)-9-oxohexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3 '-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 5 
• 879132-50-0 5-amino-1‘-((2-(trimethylsilyl)ethoxy)methyl)-1,3-dihydrospiro[indene-2,3’-pyrrolo[2,3-b]pyridin]-2’(1’H)-one 

Relevant articles and documents

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

COMPOUNDS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds;and intermediates useful in the preparation of the compounds.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I) (wherein variables A1, A2, A3, ring-B, m, n, J, E1, E2, E3, R5, RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, an